domingo, 29 de noviembre de 2015
ACTUALIZACIÓN MÉDICO-CONTINUADA EN ENFERMEDADES EPIDEMIOLÓGICAMENTE "COMUNICABLES" ► NUEVO CAPÍTULO MÉDICO ► Advanced Molecular Detection Clips Content || Public Health Genomics Knowledge Base (v1.0)
Public Health Genomics Knowledge Base (v1.0)
los capítulos incluidos en esta sección, se actualizarán semanalmente, incorporando documentos y accesos a nuevas bases de datos que actualmente están en desarrollo... los contenidos, como es costumbre en secciones avanzadas, están únicamente en idioma inglés y reflejan los últimos contenidos editados en cada materia en todo el mundo...
Advanced Molecular Detection(AMD) Clips are selected weekly from a variety of sources, including PubMed, journal tables of contents, and online media. Special emphasis is given to the use of next-generation genetic sequencing in public health surveillance, investigation, and development of new diagnostics and interventions. The collection is not comprehensive but aims to capture highlights, while surveying a wide range of topics. CDC-authored articles are flagged.
Multi-Center Evaluation of the Xpert Norovirus Assay for Detection of Norovirus GI and GII in Fecal Specimens. Norovirus is the most common cause of sporadic gastroenteritis and outbreaks worldwide. The rapid identification of norovirus has important implications for infection prevention measures, and may reduce the need for additional diagnostic testing. The Xpert Norovirus Assay recently received FDA clearance for the detection and differentiation of norovirus genogroups I and II (GI and GII), which account for the vast majority of infections. In this study, we evaluated the performance of the Xpert Norovirus Assay with both fresh, prospectively collected (n=914) and frozen, archived (n=489) fecal specimens. A Centers for Disease Control (CDC) composite reference method was used as the gold standard for comparison. For both prospective and frozen specimens, the Xpert Norovirus Assay showed a positive percent agreement (PPA) and negative percent agreement (NPA) of 98.3% and 98.1% for GI, and 99.4% and 98.2% for GII, respectively. Norovirus prevalence in the prospective specimens (collected from March to May of 2014) was 9.9% (n=90), with the majority of positives caused by genogroup II (82%, n=74). The positive predictive value (PPV) of the Xpert Norovirus Assay was 75% for GI whereas it was 86.5% for GII positive specimens. The negative predictive value (NPV) for GI and GII was 100% and 99.9%, respectively.